On 30 August, at this year's European Society of Cardiology (ESC) conference, during a late-breaking science session on the topic of "Renal Failure and Cardiovascular Disease," Professor Kenneth ...
On Thursday, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for an update for Novo Nordisk A/S’ (NYSE:NVO) Ozempic (once-weekly subcutaneous ...
Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes. The approval makes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results